| Species |
Human |
| Protein Construction |
BSPII (Phe17-Gln317)
Accession # P21815 |
His |
| N-term |
C-term |
|
| Purity |
> 95% as determined by BisTris PAGE
> 95% as determined by HPLC |
| Endotoxin Level |
Less than 1EU per μg by the LAL method. |
| Expression System |
HEK293 |
| Theoretical Molecular Weight |
34.3 kDa |
| Apparent Molecular Weight |
Due to glycosylation, the protein migrates to 70-80 kDa based on Bis-Tris PAGE result. |
| Formulation |
Lyophilized from 0.22μm filtered solution in PBS (pH 7.4). |
| Reconstitution |
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water. |
| Storage & Stability |
Upon receiving, the product remains stable up to 6 months at -20 °C or below. Upon reconstitution, the product should be stable for 3 months at -80 °C. Avoid repeated freeze-thaw cycles. |
| Target Background |
IBSP (Integrin Binding Sialoprotein) is a Protein Coding gene. Diseases associated with IBSP include Fibrous Dysplasia and Chondromalacia. Among its related pathways are Degradation of the extracellular matrix and Cytoskeletal Signaling.The protein encoded by this gene is a major structural protein of the bone matrix. It constitutes approximately 12% of the noncollagenous proteins in human bone and is synthesized by skeletal-associated cell types, including hypertrophic chondrocytes, osteoblasts, osteocytes, and osteoclasts. |
| Synonyms |
BNSP; BSP 2; BSP II; BSP; BSP-II; IBSP; SP II; SPII; SP-II |
For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.
